You are here

How Gilead arrived at US$1,000 a pill price

What sets pricing is not R&D costs but potential insurer reaction and the chance to set a price benchmark: report

MONEY EARNER: A Gilead scientist working on the hepatitis C drug. Sovaldi and Harvoni have been among the fastest-selling drugs in history, with US$20.8 billion in combined US sales since Sovaldi was launched in December 2013.

New York

FROM the start, the miracle drug was expected to carry a high price tag: US$36,000 to treat each patient.

Over the two years leading up to the medicine's 2013 launch, Gilead Sciences Inc executives and advisers inched the number higher, to about US$65,000, then to US$81,